EZH2 and neoplasm: Consistent with our in vitro studies, stable reconstitution of Ezh2, but not Ezh2 F667I or ΔSET mutant, largely abrogated the tumor-suppressive effects by the targeted Usp22 inhibition (Figure 4, J and K, and Supplemental Figure 9, A and B).